Durvalumab (D) +/- tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic (m) NSCLC: AE management in POSEIDON.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Byoung Chul Cho, Niels Reinmuth, Alexander Luft, Jorge Alatorre-Alexander, Sarayut Lucien Geater, Dmytro Trukhin, Sang-We Kim, Grygorii Ursol, Maen A. Hussein, Farah Louise Lim, Cheng-Ta Yang, Luiz H. Araujo, Haruhiro Saito, Miriam Marotti, Karen Barrett, Xiaojin Shi, Solange Peters, Edward B. Garon, Tony S. K. Mok, Melissa Lynne Johnson
Institutions: Yonsei University, Yonsei Cancer Hospital, Asklepios Fachkliniken München-Gauting, Instituto Nacional de Enfermedades Respiratorias, Prince of Songkla University, Asan Medical Center, University of Ulsan, Queen Mary University of London, Chang Gung Memorial Hospital, Taoyuan Chang Gung Memorial Hospital, Linkou Chang Gung Memorial Hospital, Instituto Nacional de Câncer - INCA, Kanagawa Cancer Center, AstraZeneca (United Kingdom), Centre Hospitalier Universitaire Vaudois, University of California, Los Angeles, Chinese University of Hong Kong, Sarah Cannon, Tennessee Oncology
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4281690679